缬沙坦联合百令胶囊对IgA肾病患者尿蛋白、尿渗透压的影响及其临床安全性的研究

目的:探讨缬沙坦联合百令胶囊治疗IgA肾病患者尿蛋白、尿渗透压的影响及其临床安全性。方法:将96例患者随机分为观察组和对照组各48例。2组均给予缬沙坦口服治疗,观察组同时加用百令胶囊,1.0 g/次,3次/d。2组均连续治疗1个月。测定2组治疗前后24小时尿蛋白定量、尿渗透压、血压、血常规(血红蛋白(HB)、白细胞计数(WBC)、血小板计数(PLT)]、总胆红素(TBIL)、血钾(K+),观察头痛、头晕、恶心等不良反应发生情况。结果:24小时尿蛋白定量、尿渗透压2组治疗后均明显改善(P0.05),观察组改善较对照组更明显(P0.05)。血压、血常规、肝功能、血钾等指标2组治疗前后比较,差异无统计学意义(P0.05)。观察组出现头痛1例,咳嗽2例,腹泻1例;对照组出现头晕2例,咳嗽1例,恶心1例。2组不良反发生情况比较,差异无统计学意义(P0.05)。结论:缬沙坦联合百令胶囊可降低IgA肾病患者尿蛋白及尿渗透压,且临床安全性指标评价良好,未见不良发应。

Study on the Influence of Valsartan and BaiLing Capsule on Urine Protein and Urine Osmotic Pressure of Patients with IgA Nephropathy and its Clinical Safety

Objective: To explore valsartan and BaiLing capsule on urine protein and urine osmotic pressure of patients with IgA nephropathy and its clinical safety. Methods: 96 cases were randomly divided into the observation group and the control group, each group 48 cases. Both groups were treated with valsartan by oral medication, the observation group was given BaiLing capsule at the same time, once one g, three times one day. Treatment for one month for both groups. Urine protein quantity (UPQ), urine osmotic pressure, blood pressure and blood routine(HB, WBC, PLT, TBIL and K+) were measured at 24 hours before and after treatment in both groups, the occurrence situations of dizziness, headache and nausea were observed. Results: 24 h UPQ and urine osmotic pressure improved obviously in both groups after treatment(P<0.05), the observation group was more obvious than the control group (P<0.05). Headache one case, cough two cases, diarrhea one case in the observation group; dizziness two cases, cough one case, nausea one case in the control group. Compared occurence situations of adverse reaction between two groups, there were no statistical differences (P>0.05). Compared blood pressure, blood routine, liver function and K+ before and after treatment between two groups, there were no statistical differences (P>0.05). Conclusion:Valsartan and BaiLing capsule can reduce urine protein and urine osmotic pressure of patients with IgA nephropathy, the evaluation for clinical safety index is good, no adverse reaction.